FOR ELIGIBLE PATIENTS WITH HER2+ BREAST CANCER
Herceptin HYLECTA™ is a subcutaneous injection administered over ~2‑5 minutes that most patients preferred over IV trastuzumab*1
Herceptin HYLECTA was approved based on two Phase 3 clinical studies in HER2+ EBC: HannaH (non-inferiority study versus IV trastuzumab based on co-primary PK and efficacy endpoints) and SafeHER (safety and tolerability study).1
*In the PrefHER study, 86% (199/231) of patients
preferred administration of Herceptin HYLECTA over IV trastuzumab.
See data below.
EBC=early breast cancer; HER2=human epidermal growth factor receptor 2; IV=intravenous; pCR=pathological complete response; PK=pharmacokinetics.
Dosing and Administration
Review details on how to administer Herceptin HYLECTA
Find information on financial assistance programs for your patients